Clinical trial · Observational
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
NCT06863870CI-TRIAL-00086882active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with advanced melanoma (uval, mucosal, of unknown origin). It also aims to verify whether their expression can be related to the prognosis of the disease and the response to treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma Neoplasms | Uveal Melanoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Melanoma circulating tumor cell (CTC) count (number of CTC/ml)
- timeFrame
- At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
- description
- Evaluate CTCs count (number/ml) in patients with metastatic UM, MM and MUP
- measure
- Circulating microRNAs (copies/ml)
- timeFrame
- At enrollment and at every scheduled follow-up visits throughtout the study (24 months)
- description
- Evaluate circulating microRNAs expression (copies/ul) in patients with metastatic UM, MM and MUP
Secondary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- Throughtout the study duration (24 months) for a minumum of 6 months for each patient
- description
- Evaluate OS throughtout the study period in order to correlate levels of CTC and microRNA with OS of patients with metastatic UM, MM and MUP
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of UM, MM or MUP * Diagnosis of metastatic disease * Age ≥ 18 years, at the time of the tissue collection Exclusion Criteria: * Personal medical history of concomitant other cancer
References
Publications (0)
Data not yet available
No reference posted for this study.